Online inquiry

IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12056MR)

This product GTTS-WQ12056MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NRP1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001024628.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8829
UniProt ID O14786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12056MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10680MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ8195MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ4104MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ14450MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ14056MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ14527MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ15950MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ10516MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW